vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Safehold Inc. (SAFE). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $97.9M, roughly 1.9× Safehold Inc.). Safehold Inc. runs the higher net margin — 28.5% vs 13.3%, a 15.1% gap on every dollar of revenue. On growth, Safehold Inc. posted the faster year-over-year revenue change (6.5% vs -1.8%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 2.5%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.
AMPH vs SAFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $97.9M |
| Net Profit | $24.4M | $27.9M |
| Gross Margin | 46.8% | 98.6% |
| Operating Margin | 19.4% | 27.4% |
| Net Margin | 13.3% | 28.5% |
| Revenue YoY | -1.8% | 6.5% |
| Net Profit YoY | -35.7% | 7.1% |
| EPS (diluted) | $0.51 | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $97.9M | ||
| Q3 25 | $191.8M | $96.2M | ||
| Q2 25 | $174.4M | $93.8M | ||
| Q1 25 | $170.5M | $97.7M | ||
| Q4 24 | $186.5M | $91.9M | ||
| Q3 24 | $191.2M | $90.7M | ||
| Q2 24 | $182.4M | $89.9M | ||
| Q1 24 | $171.8M | $93.2M |
| Q4 25 | $24.4M | $27.9M | ||
| Q3 25 | $17.4M | $29.3M | ||
| Q2 25 | $31.0M | $27.9M | ||
| Q1 25 | $25.3M | $29.4M | ||
| Q4 24 | $38.0M | $26.0M | ||
| Q3 24 | $40.4M | $19.3M | ||
| Q2 24 | $37.9M | $29.7M | ||
| Q1 24 | $43.2M | $30.7M |
| Q4 25 | 46.8% | 98.6% | ||
| Q3 25 | 51.4% | 98.5% | ||
| Q2 25 | 49.6% | 99.1% | ||
| Q1 25 | 50.0% | 98.8% | ||
| Q4 24 | 46.5% | 98.8% | ||
| Q3 24 | 53.3% | 98.8% | ||
| Q2 24 | 52.2% | 98.8% | ||
| Q1 24 | 52.4% | 98.8% |
| Q4 25 | 19.4% | 27.4% | ||
| Q3 25 | 13.2% | 25.9% | ||
| Q2 25 | 24.2% | 25.5% | ||
| Q1 25 | 21.9% | 25.9% | ||
| Q4 24 | 24.2% | 24.6% | ||
| Q3 24 | 29.8% | 17.5% | ||
| Q2 24 | 30.3% | 26.7% | ||
| Q1 24 | 27.9% | 26.4% |
| Q4 25 | 13.3% | 28.5% | ||
| Q3 25 | 9.0% | 30.5% | ||
| Q2 25 | 17.8% | 29.8% | ||
| Q1 25 | 14.8% | 30.1% | ||
| Q4 24 | 20.4% | 28.3% | ||
| Q3 24 | 21.1% | 21.3% | ||
| Q2 24 | 20.8% | 33.0% | ||
| Q1 24 | 25.1% | 33.0% |
| Q4 25 | $0.51 | $0.38 | ||
| Q3 25 | $0.37 | $0.41 | ||
| Q2 25 | $0.64 | $0.39 | ||
| Q1 25 | $0.51 | $0.41 | ||
| Q4 24 | $0.74 | $0.36 | ||
| Q3 24 | $0.78 | $0.27 | ||
| Q2 24 | $0.73 | $0.42 | ||
| Q1 24 | $0.81 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $21.7M |
| Total DebtLower is stronger | $608.7M | $4.6B |
| Stockholders' EquityBook value | $788.8M | $2.4B |
| Total Assets | $1.6B | $7.2B |
| Debt / EquityLower = less leverage | 0.77× | 1.90× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $21.7M | ||
| Q3 25 | $276.2M | $12.1M | ||
| Q2 25 | $231.8M | $13.9M | ||
| Q1 25 | $236.9M | $17.3M | ||
| Q4 24 | $221.6M | $8.3M | ||
| Q3 24 | $250.5M | $15.6M | ||
| Q2 24 | $217.8M | $13.4M | ||
| Q1 24 | $289.6M | $11.3M |
| Q4 25 | $608.7M | $4.6B | ||
| Q3 25 | $608.6M | $4.5B | ||
| Q2 25 | $607.7M | $4.4B | ||
| Q1 25 | $603.9M | $4.3B | ||
| Q4 24 | $601.6M | $4.3B | ||
| Q3 24 | $596.4M | $4.3B | ||
| Q2 24 | $586.9M | $4.2B | ||
| Q1 24 | $594.0M | $4.1B |
| Q4 25 | $788.8M | $2.4B | ||
| Q3 25 | $776.7M | $2.4B | ||
| Q2 25 | $757.5M | $2.4B | ||
| Q1 25 | $751.3M | $2.4B | ||
| Q4 24 | $732.3M | $2.3B | ||
| Q3 24 | $727.7M | $2.3B | ||
| Q2 24 | $713.3M | $2.3B | ||
| Q1 24 | $672.4M | $2.3B |
| Q4 25 | $1.6B | $7.2B | ||
| Q3 25 | $1.7B | $7.1B | ||
| Q2 25 | $1.6B | $7.1B | ||
| Q1 25 | $1.6B | $6.9B | ||
| Q4 24 | $1.6B | $6.9B | ||
| Q3 24 | $1.5B | $6.8B | ||
| Q2 24 | $1.5B | $6.8B | ||
| Q1 24 | $1.6B | $6.7B |
| Q4 25 | 0.77× | 1.90× | ||
| Q3 25 | 0.78× | 1.89× | ||
| Q2 25 | 0.80× | 1.87× | ||
| Q1 25 | 0.80× | 1.85× | ||
| Q4 24 | 0.82× | 1.84× | ||
| Q3 24 | 0.82× | 1.88× | ||
| Q2 24 | 0.82× | 1.81× | ||
| Q1 24 | 0.88× | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $47.8M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $47.8M | ||
| Q3 25 | $52.6M | $-1.4M | ||
| Q2 25 | $35.6M | $28.0M | ||
| Q1 25 | $35.1M | $8.9M | ||
| Q4 24 | $29.0M | $37.9M | ||
| Q3 24 | $60.0M | $8.3M | ||
| Q2 24 | $69.1M | $24.8M | ||
| Q1 24 | $55.3M | $-3.1M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | 1.72× | ||
| Q3 25 | 3.03× | -0.05× | ||
| Q2 25 | 1.15× | 1.00× | ||
| Q1 25 | 1.39× | 0.30× | ||
| Q4 24 | 0.76× | 1.45× | ||
| Q3 24 | 1.48× | 0.43× | ||
| Q2 24 | 1.82× | 0.83× | ||
| Q1 24 | 1.28× | -0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
